This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split
Psychedelics biotech firm Clearmind Medicine Inc.
SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes
SciSparc Ltd. (NASDAQ: SPRC) announced that Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the company's collaboration with Clearmind.
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd.
SciSparc Announces Additional Pre-Clinical Results Of Psychedelic-Based Treatment For Cocaine Addiction Using MEAI
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment
TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage
Psyched: Christie’s Launches NFT Collection Supporting Psychedelic Science, Origin’s Listing On CSE Gives Retail Investors Access To Private Companies
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs.
SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction
SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine addiction.
Patent For Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine
India's Office of the Controller-General of Patents, Designs and Trademarks granted approval for a new compound created by the biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF).
High Hopes For Alcohol Use Disorder Treatment: Clearmind’s Successful Pre-IND Meeting With The FDA
The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND New Drug Application stage.
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum.